MS

Rationing and deprivation in risk sharing schemes

Chris Sampson
March 7, 2012July 13, 2018
Efficiency and Equity

Here in the UK, NICE sometimes advises against the provision of particular drugs, by the NHS, on the grounds that evidence does not indicate them to be cost-effective. In some cases it appears that these ‘rejections’ are the result of… Read More »Rationing and deprivation in risk sharing schemes

Cancer drugs and public preferences

Chris Sampson
December 2, 2011July 13, 2018
6 Comments
Health and its Value

Last year the UK government announced the establishment of a £600 million cancer drug fund, to be spent over 3 years. This represents a minuscule amount of money compared to the NHS’s annual budget, which is in excess of £100,000,000,000. However, it… Read More »Cancer drugs and public preferences

MS

Cancer drugs and public preferences

Research Associate

Research Fellow (Health Economics)

Principal Health Economist and Infectious Disease Modeller